View an enhanced version of
our Annual Report.
View an enhanced version
of our Proxy Statement.
Request Materials
Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.
Please vote your proxy online now or by phone by dialing 866-249-5094.
June 17, 2026
8:00 AM ET
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first medication approved by the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis
(consistent with stage F4c).